Google
NVCT — NUVECTIS PHARMA INC (Healthcare >> Biotechnology)
NVCT FAQ
What is NVCT's ROE?
NUVECTIS PHARMA INC reports a Return on Equity (ROE) of -191.00%.
What is NVCT's dividend yield?
NUVECTIS PHARMA INC offers a dividend yield of 0.00%.
What is NVCT's Deepscope Quality Score?
Deepscope rates NVCT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NVCT?
Deepscope's AI Timing Score for NVCT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NVCT belong to?
NUVECTIS PHARMA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 10.71
Price
0.20
(1.90%)
Day Change
|
|
|---|
NVCT, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 10.71 |
| PBV / Sector |
19.61 / 4.91
|
| Earning Per Share | -1.04 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
0.98 M
GREAT
|
| Average 1W Daily Value |
0.69 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:36 |
| Symbol | NVCT |
| Name | NUVECTIS PHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 26.53 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 278.78 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Bridge Plaza, Fort Lee, NJ, United States, 07024
Phone: 201 614 3150
Website: https://www.nuvectis.com
Sector: Healthcare >> Biotechnology
Description: Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
